[go: up one dir, main page]

ES449257A1 - PROCESS FOR THE PREPARATION OF NEW 16-ETERS OF FUSID ACID DERIVATIVES. - Google Patents

PROCESS FOR THE PREPARATION OF NEW 16-ETERS OF FUSID ACID DERIVATIVES.

Info

Publication number
ES449257A1
ES449257A1 ES449257A ES449257A ES449257A1 ES 449257 A1 ES449257 A1 ES 449257A1 ES 449257 A ES449257 A ES 449257A ES 449257 A ES449257 A ES 449257A ES 449257 A1 ES449257 A1 ES 449257A1
Authority
ES
Spain
Prior art keywords
radical
formula
compound
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES449257A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharmaceutical Products Ltd AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB26989/75A external-priority patent/GB1523803A/en
Application filed by Leo Pharmaceutical Products Ltd AS filed Critical Leo Pharmaceutical Products Ltd AS
Publication of ES449257A1 publication Critical patent/ES449257A1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Process for the preparation of new 16-ethers of derivatives of fusidic acid, of formula I **(See formula)** wherein the C24-25 bond is a single or double bond, and where C1 and C2 represent (see formula) or oxygen; A represents oxygen, sulfur, or a sulfinyl radical; R1 represents a straight or branched chain alkyl radical having 1 to 8 carbon atoms, an alkenyl or alkynyl radical having 2 to 6 carbon atoms, a cycloalkyl radical having 3 to 7 ring carbon atoms alicyclic, an aryl, aralkyl, or heterocyclylalkyl radical, or an heterocyclic radical having 5 or 6 atoms per ring and containing oxygen, sulfur, or nitrogen atoms, optionally all radicals being substituted R1; and the pharmaceutically acceptable salts and easily hydrolyzable esters thereof, consisting of reacting a compound of formula Vb **(See formula)** wherein Q1 is Q1 or (see formula), where R2 is an alkanoyl, aralkanoyl or aroyl radical; Q2 is as defined above; Y represents, chlorine, bromine or iodine; and R3 represents a straight or ratified alkyl radical, having 1 to 6 carbon atoms, an aralkyl radical, an alkanoyl- or aroylmethyl radical, an alkanoyl- or aroyl-oxyalkyl radical, an alkyloxymethyl or cyanomethyl radical; with a compound of formula VII: R1-A-H, where R1 is as defined above and A represents oxygen or sulfur, giving a compound of formula VIII: **(See formula)** wherein Q1, Q2, R1 and R3 are as defined above, and A is oxygen or sulfur, a compound which is subsequently subjected to hydrolysis, if desired, and a compound of formula I, where A is sulfur, it is optionally oxidized to a compound of formula I, where A is a sulfinyl radical; and the free acid can be transformed into a pharmaceutically acceptable salt or an easily hydrolyzable ester thereof. (Machine-translation by Google Translate, not legally binding)
ES449257A 1975-06-25 1976-06-25 PROCESS FOR THE PREPARATION OF NEW 16-ETERS OF FUSID ACID DERIVATIVES. Expired ES449257A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB26989/75A GB1523803A (en) 1975-06-25 1975-06-25 16-ethers of fusidic acid derivatives
GB4622975 1975-11-07

Publications (1)

Publication Number Publication Date
ES449257A1 true ES449257A1 (en) 1977-12-16

Family

ID=26258548

Family Applications (1)

Application Number Title Priority Date Filing Date
ES449257A Expired ES449257A1 (en) 1975-06-25 1976-06-25 PROCESS FOR THE PREPARATION OF NEW 16-ETERS OF FUSID ACID DERIVATIVES.

Country Status (18)

Country Link
JP (1) JPS523051A (en)
AT (1) AT345979B (en)
AU (1) AU500027B2 (en)
CA (1) CA1064906A (en)
DE (1) DE2628360C2 (en)
DK (1) DK143905C (en)
ES (1) ES449257A1 (en)
FI (1) FI55852C (en)
FR (1) FR2315296A1 (en)
GR (1) GR60362B (en)
IE (1) IE43478B1 (en)
IT (1) IT1062245B (en)
LU (1) LU75239A1 (en)
NL (1) NL7606983A (en)
NZ (1) NZ181107A (en)
PT (1) PT65261A (en)
SE (1) SE7607322L (en)
SU (1) SU799670A3 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581335A (en) * 1976-07-05 1980-12-10 Leo Pharm Prod Ltd 16-s-acyl derivatives of fusidic acid
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
JP3350048B2 (en) * 1989-07-07 2002-11-25 アンドルシェルシュ・インコーポレイテッド Methods for treating androgen-related diseases
TW239145B (en) * 1992-05-21 1995-01-21 Endorech Inc

Also Published As

Publication number Publication date
IT1062245B (en) 1983-09-20
JPS6350360B2 (en) 1988-10-07
FI55852C (en) 1979-10-10
FR2315296A1 (en) 1977-01-21
DE2628360C2 (en) 1986-11-06
SU799670A3 (en) 1981-01-23
CA1064906A (en) 1979-10-23
IE43478L (en) 1976-12-25
FI55852B (en) 1979-06-29
GR60362B (en) 1978-05-19
PT65261B (en) 1977-12-07
AU1525076A (en) 1978-01-05
NZ181107A (en) 1978-11-13
DK285776A (en) 1976-12-26
LU75239A1 (en) 1977-03-16
DK143905C (en) 1982-04-19
SE7607322L (en) 1976-12-26
NL7606983A (en) 1976-12-28
AU500027B2 (en) 1979-05-10
JPS523051A (en) 1977-01-11
DE2628360A1 (en) 1977-01-13
FR2315296B1 (en) 1980-11-07
ATA438776A (en) 1978-02-15
PT65261A (en) 1976-07-01
IE43478B1 (en) 1981-03-11
FI761863A7 (en) 1976-12-26
AT345979B (en) 1978-10-10
DK143905B (en) 1981-10-26

Similar Documents

Publication Publication Date Title
ATE135709T1 (en) ERYTHROMYCIN DERIVATIVES, THEIR PROCESS FOR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
SE7608641L (en) TETRAHYDROISOKINOLINE DERIVATIVES
GB1513824A (en) 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
NL7505375A (en) NEW PENICILLIN AND CEPHALOSPORIN DERIVATIVES AND METHOD FOR PREPARING THEM.
GB1491510A (en) 1-nitrophenylquinazoline-2,4(1h,3h)-diones
DE3876813D1 (en) 3 (2H) PYRIDAZINONE, METHOD FOR THE PRODUCTION THEREOF AND ITS CONTAINER AGAINST SRS-A.
ATE110386T1 (en) CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND ANTIBACTERIAL PREPARATIONS.
IE44263L (en) Fusidic acid derivatives
ATE71621T1 (en) SUBSTITUTED AZOLYLETHANOL DERIVATIVES AS PLANT GROWTH REGULATORS.
ES8506718A1 (en) Benzofuran and benzothiophene-carboxylic-acid derivatives.
ATE34394T1 (en) THERAPEUTICally ACTIVE DI, TRI, TETRA AND PENTA AZA INDENE.
ES449257A1 (en) PROCESS FOR THE PREPARATION OF NEW 16-ETERS OF FUSID ACID DERIVATIVES.
SE8306370D0 (en) NOVEL ANDROSTANE-17BETA-CARBOXYLIC ACID ESTERS, A PROCESS AND INTERMEDIATES FOR THEIR PREPARATION, COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
DE69324066D1 (en) 4-phenylcarbamoyl-3-isoxazole carboxylic acid derivatives with anti-inflammatory activity
ATE37872T1 (en) PHENYLINDEN DERIVATIVES, THEIR SALTS, AND PROCESSES FOR THEIR PRODUCTION.
ES470916A1 (en) 4-Hydroxy-2-quinolinone-3-carboxylic acids, their preparation and pharmaceutical compositions containing them.
ES445661A1 (en) Acetylene derivatives
JPS5559127A (en) Novel intermediate compound for producing prostanoids and its manufacture
KR850000455A (en) Method for preparing cephalosporin ester derivative
GB1460427A (en) Phenothiazine derivatives
GB1436502A (en) Amide derivatives of 3-benzoylphenyl-alkanoic acids
ES446743A1 (en) Crystalline cephalosporin salts
GB1504683A (en) Pharmaceutical compositions containing substituted pyrimido-quinoline derivatives
ES548074A1 (en) 2-Substituted amino-4(1H)-pyrimidone derivatives, their production, and medical compositions containing them.
GB1434645A (en) Tetrazole coumarin derivatives